PharmEasy IPO
PharmEasy is a digital healthcare platform operated through the API Holdings ecosystem, offering online pharmacy, diagnostics, teleconsultation, healthcare technology and related healthcare services. The company had earlier proposed an IPO through API Hol
PharmEasy IPO Details
PharmEasy IPO is the proposed public offering associated with API Holdings Limited, the parent company of the PharmEasy healthcare ecosystem. API Holdings operates across digital pharmacy, diagnostics, pharmaceutical distribution, hospital procurement and healthcare technology. The company had filed its DRHP with SEBI in 2021, but the earlier IPO proposal was subsequently withdrawn. A fresh IPO issue size, price band, lot size and listing schedule are currently not available.
PharmEasy IPO Timeline (Tentative)
PharmEasy IPO does not currently have an official IPO opening or closing date. API Holdings Limited had earlier filed its DRHP with SEBI in November 2021, but that IPO proposal did not proceed to listing. Any new IPO dates will be available only after the company files fresh offer documents.
| Event | Tentative Date |
|---|---|
| IPO Opens | |
| IPO Closes | |
| Basis of Allotment | |
| Refund Initiation | |
| Credit of Shares to Demat | |
| Listing Date |
PharmEasy IPO Lot Size
The PharmEasy IPO lot size is currently not available because the company has not announced a fresh IPO price band or minimum application size. The lot size will be determined from the final issue price and application structure specified in the RHP.
| Application | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | |||
| Retail (Max) | |||
| S-HNI (Min) | |||
| S-HNI (Max) | |||
| B-HNI (Min) |
PharmEasy IPO Subscription
PharmEasy IPO subscription status is currently not available because there is no active IPO issue open for bidding. Category-wise subscription figures for QIB, NII and Retail investors will be updated after a future IPO opens for subscription.
| Category | Subscription (times) |
|---|---|
| QIB | |
| NII | |
| RII | |
| Total |
About PharmEasy
PharmEasy is a digital healthcare platform associated with API Holdings Limited, an integrated healthcare company operating across online pharmacy, diagnostics, pharmaceutical distribution, hospital procurement and healthcare technology. The PharmEasy brand and technology platform form part of the group's digital healthcare ecosystem, while API Holdings has expanded its operations through acquisitions and investments across the healthcare value chain.
API Holdings was incorporated in 2019 and became a public limited company in 2021. The company's business has developed beyond online pharmacy into a broader healthcare platform covering medicines, diagnostics, teleconsultation, pharmaceutical distribution and technology-enabled healthcare services. The group has also expanded through acquisitions including Medlife and Thyrocare.
The PharmEasy marketplace is operated by Axelia Solutions Private Limited, while API Holdings owns the PharmEasy brand and its proprietary technology and licenses the brand and technology to the operating entity. API Holdings also has interests in other healthcare businesses, including Thyrocare and businesses involved in pharmaceutical distribution and hospital procurement.
The company had filed its DRHP with SEBI for an IPO in November 2021. The earlier IPO proposal was subsequently withdrawn, and therefore the historical IPO terms cannot be treated as the current issue structure. Any future PharmEasy IPO will require fresh offer documents containing the updated issue size, valuation, financial information, objects and risk factors.
Strengths
- Integrated digital healthcare ecosystem covering pharmacy, diagnostics and healthcare services.
- Recognised PharmEasy brand and established digital healthcare platform.
- Diversified presence across pharmaceutical distribution, diagnostics and healthcare technology.
- Technology-enabled supply-chain and healthcare delivery capabilities.
- Expansion through acquisitions such as Medlife and Thyrocare.
Risks to Consider
- The company operates in a highly competitive digital healthcare and pharmaceutical market.
- The pharmaceutical and healthcare businesses are subject to extensive regulatory requirements.
- API Holdings has historically reported significant losses.
- The business requires continued investment in technology, logistics and healthcare infrastructure.
- Competition from online and offline pharmacies, diagnostic companies and other healthcare platforms may affect growth and margins.
- Any future IPO valuation will need to be evaluated against the company's profitability, debt and cash-flow position.
PharmEasy Financials (₹ Cr)
API Holdings reported consolidated revenue from operations of ₹6,643.94 crore in FY2023, ₹5,664.29 crore in FY2024 and ₹5,872.16 crore in FY2025. Profit after tax remained negative during these years, with the consolidated loss reducing from ₹5,211.73 crore in FY2023 to ₹2,533.51 crore in FY2024 and ₹1,572.39 crore in FY2025. Total assets stood at ₹8,256.42 crore in FY2023, ₹8,389.66 crore in FY2024 and ₹6,976.58 crore in FY2025, while net worth increased from ₹2,436.89 crore to ₹3,272.28 crore during the same period.
| Period | Revenue | PAT | Total Assets | Net Worth |
|---|---|---|---|---|
| FY2023 | 6,643.94 | -5,211.73 | 8,256.42 | 2,436.89 |
| FY2024 | 5,664.29 | -2,533.51 | 8,389.66 | 2,588.31 |
| FY2025 | 5,872.16 | -1,572.39 | 6,976.58 | 3,272.28 |
KPIs & Valuation
API Holdings reported a consolidated diluted EPS of approximately ₹-2.41 for FY2025 based on its FY2025 consolidated earnings and weighted share capital. The FY2025 net worth was ₹3,272.28 crore, which translates into a book value of approximately ₹5.02 per share based on the reported equity share capital. The company reported negative profitability ratios during FY2025. IPO-specific P/E figures cannot be calculated because there is no current IPO price band.
Objects of the Issue
The objects of a new PharmEasy IPO are currently not available because no fresh RHP has been announced. API Holdings had earlier proposed an IPO, but the earlier offer documents cannot be used as the objects of a future issue. The earlier IPO proposal included a fresh issue intended to support the company's growth and strategic requirements. The historical offer documents also provided for purposes including repayment or prepayment of borrowings, funding acquisitions and strategic initiatives, and general corporate purposes. The company proposed to utilise the IPO proceeds for:
- Funding organic growth initiatives.
- Funding acquisitions and strategic initiatives.
- Repayment or prepayment of certain borrowings.
- General corporate purposes.
Promoters, Lead Managers & Registrar
API Holdings Limited's historical IPO documentation identified the company as having no identifiable promoter. The earlier IPO proposal had Kotak Mahindra Capital Company Limited, Morgan Stanley India Company Private Limited, BofA Securities India Limited, Citigroup Global Markets India Private Limited and JM Financial Limited as the book running lead managers, with Link Intime India Private Limited as the registrar to the offer. These details relate to the historical IPO proposal and should be reconfirmed from fresh offer documents if a new PharmEasy IPO is announced.
Promoters
Lead Managers (BRLM)
Registrar
| Name | Link Intime India Private Limited |
|---|---|
| Phone | +91 22 4918 6000 |
| apiholdings@linkintime.co.in | |
| Website | www.linkintime.co.in |
PharmEasy IPO Review
PharmEasy has developed from an online pharmacy platform into a broader digital healthcare ecosystem through API Holdings Limited. The group's operations cover online healthcare, diagnostics, pharmaceutical distribution, hospital procurement and healthcare technology, giving it exposure to several segments of the healthcare value chain.
The company has expanded its operations through acquisitions, including Medlife and Thyrocare. Thyrocare strengthened the group's diagnostics presence, while other businesses have provided exposure to pharmaceutical distribution and healthcare supply-chain requirements. This integrated approach allows the group to participate across different stages of healthcare delivery.
API Holdings' consolidated financial performance has shown improvement in losses, although the company remained loss-making in FY2025. Revenue from operations increased from ₹5,664.29 crore in FY2024 to ₹5,872.16 crore in FY2025, while the consolidated loss after tax reduced to approximately ₹1,572.39 crore from ₹2,533.51 crore.
For a future IPO, investors will need to examine the latest financial performance, debt position, cash flows, profitability, valuation and proposed use of funds. Since the previous IPO proposal was withdrawn, the old IPO price and valuation should not be used to assess a new PharmEasy issue.
How to Apply
PharmEasy IPO applications cannot currently be made because there is no active PharmEasy IPO issue. If the company announces a fresh IPO in the future, investors can generally apply through ASBA or UPI using an eligible bank or stockbroker platform.
Through UPI
- Log in to your stockbroker app/website.
- Go to the IPO section.
- Select PharmEasy IPO.
- Enter the number of lots you want to apply for.
- Select the bid price. Retail investors can generally choose Cut-off when available.
- Enter your valid UPI ID.
- Submit the IPO application.
- Open your UPI app when the mandate request arrives.
- Approve the mandate using your UPI PIN.
- The application amount will be blocked in your bank account. If shares are allotted, the required amount will be debited; otherwise, the blocked amount will be released.
Prospectus & Documents
Investors can refer to API Holdings' official investor-relations page and financial reports for information about the company's business and financial performance. The historical API Holdings IPO DRHP was filed with SEBI in November 2021. Since the earlier IPO proposal did not become a completed public issue, a current RHP or Prospectus for a new PharmEasy IPO is not available.
Last updated Sep 29, 2026.